{"id":146,"date":"2022-11-17T19:49:34","date_gmt":"2022-11-17T10:49:34","guid":{"rendered":"https:\/\/gene4.knit.kagoshima-u.ac.jp\/kansen\/?page_id=146"},"modified":"2026-04-17T17:52:23","modified_gmt":"2026-04-17T08:52:23","slug":"performance","status":"publish","type":"page","link":"https:\/\/gene4.knit.kagoshima-u.ac.jp\/kansen\/?page_id=146","title":{"rendered":"Research Performance"},"content":{"rendered":"\n

\u7814\u7a76\u5b9f\u7e3e Research Performance<\/h4>\n\n\n\n

\u611f\u67d3\u5236\u5fa1\u7814\u7a76\u90e8\u9580\u8a2d\u7f6e\uff082022\u5e744\u67081\u65e5\uff09\u4ee5\u964d\u306e\u3082\u306e\u306b\u3064\u3044\u3066\u8a18\u8f09\u3057\u3066\u3044\u307e\u3059\u3002<\/p>\n\n\n\n

This information is for the establishment of the Division of Infection Control Research (April 1st, 2022) and thereafter.<\/p>\n\n\n\n

\u3010\u6b27\u6587\u539f\u8457\u8ad6\u6587\uff1aOriginal Papers\u3011<\/h5>\n\n\n\n
    \n
  1. Toyama M, Watashi K, Ikeda M, Yamashita A, Okamoto M, Moriishi K, Muramatsu M, Wakita T, Sharon A, Baba M. Novel neplanocin A derivatives as selective inhibitors of hepatitis B virus with a unique mechanism of action. 2022. Antimicrob. Agents Chemother. 66 e0207321. https:\/\/doi.org\/10.1128\/aac.02073-21<\/a>
    <\/li>\n\n\n\n
  2. Kajiya T, Sawayama H, Arima E, Okamoto M, Baba M, Toyama M, Okuya K, Ozawa M, Atsuchi N, Nishi J, Suda Y. Novel RT-PCR using sugar chain-immobilized gold-nanoparticles correlates patients' symptoms: The follow-up study of Covid-19 hospitalized patients. 2022. Viruses 14, 2577. https:\/\/doi.org\/10.3390\/v14112577<\/a>
    <\/li>\n\n\n\n
  3. Baba M, Okamoto M, Toyama M, Sakakibara N, Shimojima M, Saijo M, Niwa T, Yagi Y. Amodiaquine derivatives as inhibitors of severe fever with thrombocytopenia syndrome virus (SFTSV) replication. 2023. Antiviral Res. 210, 105479. https:\/\/doi.org\/10.1016\/j.antiviral.2022.105479<\/a>
    <\/li>\n\n\n\n
  4. Homma T*, Okamoto M*, Koharazawa R, Hayakawa M, Fushimi T, Tode C, Hirota Y, Osakabe N, Baba M, Suhara Y.(*Equal contribution\uff09Exploring novel vitamin K derivatives with anti-SARS-CoV-2 activity. 2023. ACS Omega 8, 42248-42263. https:\/\/doi.org\/10.1021\/acsomega.3c04175<\/a>
    <\/li>\n\n\n\n
  5. Koze H, Sudoh M, Onitsuka S, Okamura H, Ishikawa T, Tani F, Miyata-Yabuki Y, Shirouzu M, Baba M, Okamoto M, Hamada T. Sulfoquinovosyl diacylglycerol, a component of holy basil Ocimum tenuiflorum, inhibits the activity of the SARS-CoV-2 main protease and viral replication in vitro. 2025. J. Nat. Med. 79, 122\u2013133. https:\/\/doi.org\/10.1007\/s11418-024-01855-6<\/a>
    <\/li>\n\n\n\n
  6. Ishikawa T, Matsumoto K, Hamada T, Koze H, Baba M, Okamoto M, Sudoh M. In silico discovery of SARS-CoV-2 main protease inhibitors using docking, molecular dynamics, and fragment molecular orbital calculations. 2025. J. Phys. Chem. B. 129, 1740-1749. https:\/\/doi.org\/10.1021\/acs.jpcb.4c07920<\/a>
    <\/li>\n\n\n\n
  7. Kasula M, Toyama M, Samunuri R, Jha AK, Okamoto M, Baba M, Sharon A. Pyrazolo[3,4-d]pyrimidine-based neplanocin analogs an identified possible de novo pharmacophore as dual-target HBV inhibitor. 2025. RSC Med. Chem. 16, 1740-1745. https:\/\/doi.org\/10.1039\/D4MD00932K<\/a>
    <\/li>\n\n\n\n
  8. Aoki S*, Tanaka T, Yokoi K, Kanbe A, Morita T, Nii M, Satoh H, Kakihana M, Otaki S, Sekiguchi S, Nakamura K, Tojo T, Baba M, Okamoto M* (*Corresponding authors). Design, synthesis and anti-SARS-CoV-2 activity of amodiaquine analogs. 2025. Chem. Pharm. Bull.
    73, 355-368.     https:\/\/doi.org\/10.1248\/cpb.c24-00647<\/a>
    <\/li>\n\n\n\n
  9. Samunuri R, Toyama M, Kasula M, Jha AK, Okamoto M, Baba M, Sharon A. Synthesis, cytotoxicity, and mechanistic evaluation of 7-deazapurine-based neplanocin analogues as selective anti-HBV agents. 2025. ChemistrySelect 10, e00784. http:\/\/dx.doi.org\/10.1002\/slct.202500784<\/a><\/li>\n\n\n\n
  10. Samunuri R, Toyama M, Kasula M, Veerababu M, Mallipudi VR, Achanta RT, Rajeshkumar V, Jha AK, Baba M, Okamoto M, Sharon A. Structure-activity relationship of neplanocin A analogues for the identification of novel anti-HBV leads. 2026. Org. Biomol. Chem. 24, 3040-3053. https:\/\/doi.org\/10.1039\/D6OB00227G<\/a><\/li>\n<\/ol>\n\n\n\n
    \u3010\u7dcf\u8aac\u8ad6\u6587\uff1aReview Papers\u3011<\/h5>\n\n\n\n
      \n
    1. \u9808\u539f\u7fa9\u667a\uff0c\u5ca1\u672c\u5b9f\u4f73\uff0e\u65b0\u578b\u30b3\u30ed\u30ca\u30a6\u30a4\u30eb\u30b9\u611f\u67d3\u75c7\u3068\u305d\u306e\u5f8c\u907a\u75c7\u306b\u5bfe\u3059\u308b\u6cbb\u7642\u52b9\u679c\u3092\u4f75\u305b\u6301\u3064\u85ac\u5264\u306e\u5275\u88fd\uff0e2023\uff0eBio Industry 40 (1), 8-15\uff0e<\/li>\n\n\n\n
    2. Hirota Y, Okamoto M, Baba M, Suhara Y. Potential of fat-soluble vitamins as a platform for antiviral drug development. 2025. Bioorg. Med. Chem. Lett. 127, 130292. https:\/\/doi.org\/10.1016\/j.bmcl.2025.130292<\/a>.
      <\/li>\n<\/ol>\n\n\n\n
      \u3010\u7279\u5225\u8b1b\u6f14\u30fb\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0\uff1aSpecial Lectures and Symposiums\u3011<\/h5>\n\n\n\n
        \n
      1. \u99ac\u5834\u660c\u7bc4\uff0c\u5ca1\u672c\u5b9f\u4f73\uff0e\u65b0\u578b\u30b3\u30ed\u30ca\u30a6\u30a4\u30eb\u30b9\u611f\u67d3\u75c7\u306b\u5bfe\u3059\u308b\u6297\u30a6\u30a4\u30eb\u30b9\u85ac\u958b\u767a\u306e\u73fe\u72b6\u3068\u5c06\u6765\uff0e\u7b2c26\u56de\u65e5\u672c\u795e\u7d4c\u611f\u67d3\u75c7\u5b66\u4f1a\u7dcf\u4f1a\u30fb\u5b66\u8853\u96c6\u4f1a\u3000\u7279\u5225\u8b1b\u6f14\uff0c2022\u5e7410\u670814\u65e5\uff0c\u9e7f\u5150\u5cf6\uff0e<\/li>\n\n\n\n
      2. \u99ac\u5834\u660c\u7bc4\uff0c\u5ca1\u672c\u5b9f\u4f73\uff0e\u30d6\u30bf\u5185\u5728\u6027\u30ec\u30c8\u30ed\u30a6\u30a4\u30eb\u30b9\uff08PERV\uff09\u306b\u5bfe\u3059\u308b\u5897\u6b96\u963b\u5bb3\u5264\u306e\u7814\u7a76\uff0e\u7b2c26\u56de\u65e5\u672c\u7570\u7a2e\u79fb\u690d\u7814\u7a76\u4f1a\u3000\u7279\u5225\u30bb\u30df\u30ca\u30fc\uff0c2024\u5e742\u670817\u65e5\uff0c\u9e7f\u5150\u5cf6\uff0e<\/li>\n<\/ol>\n\n\n\n
        \u3010\u56fd\u969b\u5b66\u4f1a\u767a\u8868\uff1aInternational Conference Presentations<\/strong>\u3011<\/h5>\n\n\n\n
          \n
        1. Okamoto M, Baba M, Tanaka T, Yokoi K, Otaki S, Tojo T, Otsuki T, Kitabatake K, Tsukimoto M, Hanawa T, Kita S, Maenaka K, Kawaguchi A, Hirayama N, Aoki S. Novel quinazoline derivatives targeting SARS-CoV-2 RdRp with in vitro and in vivo efficacy. The 33rd Conference on Retroviruses and Opportunistic Infections (CROI 2026), February 25, 2026, Denver, CO, USA.<\/li>\n<\/ol>\n\n\n\n
          \u3010\u7279\u8a31\u51fa\u9858\uff1aPatent Application\u3011<\/h5>\n\n\n\n
            \n
          1. \u6297SARS-CoV-2\u85ac\uff0e\u767a\u660e\u8005\uff1a\u99ac\u5834\u660c\u7bc4\uff0c\u5ca1\u672c\u5b9f\u4f73\uff0c\u5916\u5c71\u653f\u660e\uff0c\u9752\u6728\u3000\u4f38\uff0c\u7530\u4e2d\u667a\u535a\uff0c\u6a2a\u4e95\u5065\u6c70\uff0e\u51fa\u9858\u4eba\uff1a\u56fd\u7acb\u5927\u5b66\u6cd5\u4eba\u9e7f\u5150\u5cf6\u5927\u5b66\uff0c\u5b66\u6821\u6cd5\u4eba\u6771\u4eac\u7406\u79d1\u5927\u5b66\uff0e\uff08\u56fd\u969b\u7279\u8a31\u51fa\u9858\uff09PCT\/JP2022\/42029
            \uff082022\u5e7411\u670811\u65e5\uff09\uff0e<\/li>\n\n\n\n
          2. \u6297SARS-CoV-2\u85ac\uff0e\u767a\u660e\u8005\uff1a\u99ac\u5834\u660c\u7bc4\uff0c\u5ca1\u672c\u5b9f\u4f73\uff0c\u5916\u5c71\u653f\u660e\uff0c\u6a4b\u672c\u5b8f\u6b63\uff0e\u51fa\u9858\u4eba\uff1a\u30aa\u30f3\u30b3\u30ea\u30b9\u30d0\u30a4\u30aa\u30d5\u30a1\u30fc\u30de\u682a\u5f0f\u4f1a\u793e\uff0e\uff08\u56fd\u969b\u7279\u8a31\u51fa\u9858\uff09PCT\/JP2022\/ 42332
            \uff082022\u5e7411\u670815\u65e5\uff09\uff0e<\/li>\n\n\n\n
          3. \u6297SARS-CoV-2\u5264\u53ca\u3073\u5316\u5408\u7269\u306e\u4f7f\u7528\uff0e\u767a\u660e\u8005\uff1a\u5ca1\u672c\u5b9f\u4f73\uff0c\u99ac\u5834\u660c\u7bc4\uff0c\u9808\u539f\u7fa9\u667a\uff0c\u672c\u9593\u5927\u6689\uff0e\u51fa\u9858\u4eba\uff1a\u56fd\u7acb\u5927\u5b66\u6cd5\u4eba\u9e7f\u5150\u5cf6\u5927\u5b66\uff0c\u5b66\u6821\u6cd5\u4eba\u829d\u6d66\u5de5\u696d\u5927\u5b66\uff0e\uff08\u56fd\u969b\u7279\u8a31\u7279\u9858\uff09PCT\/JP2023\/015791
            \uff082023\u5e744\u670820\u65e5\uff09\uff0e<\/li>\n\n\n\n
          4. \u30d5\u30a7\u30ca\u30f3\u30c8\u30ea\u30b8\u30ce\u30f3\u8a98\u5c0e\u4f53\u306e\u30b3\u30ea\u30f3\u5869\uff0e\u767a\u660e\u8005\uff1a\u6d66\u7530\u6cf0\u751f\uff0c\u5742\u5185\u4fe1\u8cb4\uff0c\u5742\u7530\u6643\u4e00\uff0c\u99ac\u5834\u660c\u7bc4\uff0c\u5ca1\u672c\u5b9f\u4f73\uff0c\u5916\u5c71\u653f\u660e\uff0e\u51fa\u9858\u4eba\uff1a\u30aa\u30f3\u30b3\u30ea\u30b9\u30d0\u30a4\u30aa\u30d5\u30a1\u30fc\u30de\u682a\u5f0f\u4f1a\u793e\uff0e\u7279\u98582023-081209
            \uff082023\u5e745\u670817\u65e5\uff09\uff0e<\/li>\n\n\n\n
          5. \u6297SARS-CoV-2\u85ac\uff0e\u767a\u660e\u8005\uff1a\u99ac\u5834\u660c\u7bc4\uff0c\u5ca1\u672c\u5b9f\u4f73\uff0c\u30d0\u30eb \u30c1\u30e3\u30f3\u30c9\u30e9\u30e9\u30fc\u30bf\uff0c\u30df\u30b7\u30e5\u30e9 \u30a6\u30c3\u30bf\u30e0 \u30af\u30de\u30eb\uff0c\u30b7\u30e3\u30ed\u30f3 \u30a2\u30b7\u30e7\u30fc\u30ab\uff0e\u51fa\u9858\u4eba\uff1a\u56fd\u7acb\u5927\u5b66\u6cd5\u4eba\u9e7f\u5150\u5cf6\u5927\u5b66\uff0e\u7279\u98582024-232249\uff082024\u5e7412\u670827\u65e5\uff09\uff0e<\/li>\n\n\n\n
          6. \u6297SARS-CoV-2\u85ac\uff0e\u767a\u660e\u8005\uff1a\u99ac\u5834\u660c\u7bc4\uff0c\u5ca1\u672c\u5b9f\u4f73\uff0c\u30d0\u30eb \u30c1\u30e3\u30f3\u30c9\u30e9\u30e9\u30fc\u30bf\uff0c\u30df\u30b7\u30e5\u30e9 \u30a6\u30c3\u30bf\u30e0 \u30af\u30de\u30eb\uff0c\u30b7\u30e3\u30ed\u30f3 \u30a2\u30b7\u30e7\u30fc\u30ab\uff0c\u30af\u30de\u30ea \u30b9\u30d7\u30ea\u30bf\uff0e\u51fa\u9858\u4eba\uff1a\u56fd\u7acb\u5927\u5b66\u6cd5\u4eba\u9e7f\u5150\u5cf6\u5927\u5b66\uff0e\uff08\u56fd\u969b\u7279\u8a31\u51fa\u9858\uff09PCT\/JP2025\/45786\uff082025\u5e7412\u670826\u65e5\uff09\uff0e<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

            \u7814\u7a76\u5b9f\u7e3e Research Performance \u611f\u67d3\u5236\u5fa1\u7814\u7a76\u90e8\u9580\u8a2d\u7f6e\uff082022\u5e744\u67081\u65e5\uff09\u4ee5\u964d\u306e\u3082\u306e\u306b\u3064\u3044\u3066\u8a18\u8f09\u3057\u3066\u3044\u307e\u3059\u3002 This information is for the establishment of […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_lightning_design_setting":{"layout":"default"},"footnotes":""},"class_list":["post-146","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/gene4.knit.kagoshima-u.ac.jp\/kansen\/index.php?rest_route=\/wp\/v2\/pages\/146","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/gene4.knit.kagoshima-u.ac.jp\/kansen\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/gene4.knit.kagoshima-u.ac.jp\/kansen\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/gene4.knit.kagoshima-u.ac.jp\/kansen\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/gene4.knit.kagoshima-u.ac.jp\/kansen\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=146"}],"version-history":[{"count":54,"href":"https:\/\/gene4.knit.kagoshima-u.ac.jp\/kansen\/index.php?rest_route=\/wp\/v2\/pages\/146\/revisions"}],"predecessor-version":[{"id":686,"href":"https:\/\/gene4.knit.kagoshima-u.ac.jp\/kansen\/index.php?rest_route=\/wp\/v2\/pages\/146\/revisions\/686"}],"wp:attachment":[{"href":"https:\/\/gene4.knit.kagoshima-u.ac.jp\/kansen\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=146"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}